Despite the potential importance of the cell cycle and apoptosis pathways in brain tumor etiology, little has been published regarding brain tumor risk associated with common gene variants in these pathways. Using data from a hospital-based case-control study conducted by the National Cancer Institute between 1994 and 1998, we evaluated risk of glioma (n = 388), meningioma (n = 162), and acoustic neuroma (n = 73) with respect to 12 single nucleotide polymorphisms from 10 genes involved in apoptosis and cell cycle control: CASP8, CCND1, CCNH, CDKN1A, CDKN2A, CHEK1, CHEK2, MDM2, PTEN, and TP53. We observed significantly decreased risk of meningioma with the CASP8 Ex14-271A>T variant [odds ratio (OR) AT , 0.8; 95% confidence interval (95% CI), 0.5-1.2; OR AA , 0.5; 95% CI, 0.3-0.9; P trend = 0.03] and increased risk of meningioma with the CASP8 Ex13+51G>C variant (OR GC , 1.4; 95% CI, 0.9-2.1; OR CC , 3.6; 95% CI, 1.0-13.1; P trend = 0.04). The CT haplotype of the two CASP8 polymorphisms was associated with significantly increased risk of meningioma (OR, 1.7; 95% CI, 1.1-2.6), but was not associated with risk of glioma or acoustic neuroma. The CCND1 Ex4-1G>A variant was associated with increased risk for glioma, and the Ex8+49T>C variant of CCNH was associated with increased risk of glioma and acoustic neuroma. The MDM2 Ex12+162A>G variant was associated with significantly reduced risk of glioma. Our results suggest that common variants in the CASP8, CCND1, CCNH, and MDM2 genes may influence brain tumor risk. Future research in this area should include more detailed coverage of genes in the apoptosis/cell cycle control pathways. (Cancer Epidemiol Biomarkers Prev 2007;16(8):1655 -61) 
Introduction
The processes of tumor initiation, growth, and proliferation are thought to be largely influenced by genes that regulate vital cellular functions (1) . In normal cells, DNA damage is recognized by cellular mechanisms, and responses to prevent the propagation of errors include nucleotide damage repair, activation of checkpoints to arrest the cell cycle, and/or cell apoptosis (2) . Hereditary defects in genes that regulate the crucial pathways of cell cycle control and apoptosis have been associated with a number of human malignancies, including tumors of the brain and nervous system (1) . The importance of apoptosis and cell cycle control in brain tumor etiology has also been suggested by the frequent presence of mutations or loss of expression of apoptosis/cell cycle control genes such as PTEN, CDKN2A, MDM2, TP53, NF1, and RB in brain tumors (3) .
Despite the potential importance of the cell cycle and apoptosis pathways in brain tumor etiology, very little has been published regarding brain tumor risk associated with more common gene variants in these pathways, with the exception of the TP53 gene, for which some evidence of differences in glioma and meningioma risk with common polymorphisms and haplotypes has been noted (4) (5) (6) (7) , and the CCND gene, for which no association with meningioma was observed (8) . Using data from a hospital-based case-control study conducted by the National Cancer Institute (NCI) between 1994 and 1998, we evaluated risk of three brain tumor types (glioma, meningioma, and acoustic neuroma) with respect to 12 single nucleotide polymorphisms (SNP) from 10 genes involved in apoptosis and cell cycle control: CASP8 (rs13113, rs1045485), CCND1 (rs678653, rs603965), CCNH (rs2266690), CDKN1A (rs1801270), CDKN2A (rs3731249), CHEK1 (rs506504), CHEK2 (rs2267130), MDM2 (rs769412), PTEN (rs701848), and TP53(rs1042522). These polymorphisms were selected for their common occurrence in the population, and for potential functional relevance signaled by nonsynonymous amino acid changes or occurrence in exonic or promoter regions of the gene (Table 1) .
Materials and Methods
Study Setting and Population. A detailed description of study methods can be found elsewhere (9) . Briefly, subjects for a case-control study of brain tumors were enrolled between 1994 and 1998 from three hospitals located in Phoenix, Arizona; Boston, Massachusetts; and Pittsburgh, Pennsylvania. Each hospital specializes in the treatment of brain tumors and serves as a regional referral center for the diagnosis. The study protocol was approved by the institutional review board of each participating institution, and written informed consent was obtained from each patient or proxy.
Eligible patients were 18 years or older with a first intracranial glioma, meningioma (ICD-O-2 codes 9530-9538), or acoustic neuroma (ICD-O-2 codes 9560) diagnosed at the hospital or during the 8 weeks preceding hospitalization.
Ninety-two percent of eligible brain tumor patients agreed to participate, and 489 patients with glioma, 197 with meningioma, and 96 patients with acoustic neuroma were enrolled. All diagnoses of glioma and meningioma and 96% of acoustic neuromas were confirmed by microscopy at the hospital of diagnosis.
Study controls were patients admitted to the same hospitals as cases for a variety of nonneoplastic conditions, including injuries (25%), circulatory system disorders (22%), musculoskeletal disorders (22%), and digestive disorders (12%). Controls were frequency matched in a 1:1 ratio to all brain tumor patients based on age in years (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) , 40-49, 50-59, 60-69, 70-79, and 80-99 years); race/ethnicity (non-Hispanic White, Hispanic, African-American, other); sex (male, female); hospital (Phoenix, Boston, Pittsburgh); and residential proximity to the hospital in miles (0-4, 5-14, 15-29, 30-49, 50 or more). 799 control patients, who represented 86% of all contacted controls, were enrolled.
Blood samples were collected and sent for genotyping for 388 patients with glioma (79%), 162 patients with meningioma (82%), 73 patients with acoustic neuroma (76%), and 553 controls (69%). The main obstacle to obtaining blood samples was subject refusal, with non-participation in the blood draw being higher for controls (24%) than for cases (14%).
Processing of Blood Samples and Genotyping. DNA was extracted from blood samples using a phenol-chloroform method (10) , and genotyping was conducted by the NCI Core Genotyping Facility using a medium-throughput TaqMan assay. Sequence data and assay conditions are provided online 9 (11) . Quality control (QC) specimens for the study included 15 to 34 samples from each of three individuals (A, B, C) who were not study participants (QC-A, n = 34; QC-B, n = 20; QC-C, n = 15) and duplicate samples from 89 study subjects. These specimens were collected and processed in a manner similar to study samples and were interspersed among all genotyping assays in a masked fashion. Percentage agreement between the three nonstudy replicates ranged from 97.8% to 100% for all SNPs. Concordance for duplicates was lowest for CHEK2 IVS9-200G>A (91.8%), but ranged from 97.2% to 100% for the remaining SNPs, with 100% concordance for nine of the 12 SNPs. In addition to QC specimens, each plate of Gene alterations in brain tumors (37) Abbreviation: NHL, non -Hodgkin's lymphoma. *Based on SNP500.
368 specimens included homozygous wild-type, heterozygous, and homozygous variant positive controls and one DNA negative control.
Statistical Analyses. Statistically significant departure from Hardy-Weinberg equilibrium for controls was assessed using the m 2 test. For each polymorphism, unconditional logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (95% CI) for each tumor type, adjusted for the study matching factors of age, sex, race/ethnicity, hospital, and residential proximity to the hospital. Because controls were frequency matched to all tumor types, all controls were used in the models for each tumor type. Models were run under the assumption of codominant inheritance (AA versus Aa versus aa) and dominant inheritance (AA versus Aa or aa). A score test of linear trend was conducted for each SNP using a three-level ordinal variable. To account for the fact some of our results could be false-positive findings due to chance, we calculated the probability that our findings were false positives using the false discovery rate, which reflects the expected ratio of false-positive findings to the number of significant findings (12) . We applied the false discovery rate method to the P values for trend as this allows for the fewest number of comparisons and thus degrees of freedom to assess the additive model of risk. For evaluating the false discovery rate, all sets of P trend (glioma, meningioma, and acoustic neuroma) were evaluated simultaneously.
All analyses were run separately by gender and were repeated in non-Hispanic whites (89% of the study population). Given that the protein MDM2 is a strong down-regulator of TP53, we also assessed potential interaction between polymorphisms in these two genes.
Haplotypes formed by the two CASP8 polymorphisms (D ¶ = 1.0, r 2 = 0.12) and the two CCND1 polymorphisms (D ¶ = 0.89, r 2 = 0.34) were analyzed within non-Hispanic whites. The HaploView program, version 3.32, was used to estimate haplotype block structure in controls. Haplotype frequencies were estimated using the estimation-maximization algorithm (13) , and overall differences between cases and controls (adjusted for age and sex) were assessed using the global score test in HaploStat (R version 2.2.0). The effects of individual haplotypes were estimated using unconditional logistic regression, assuming an additive model and using posterior probabilities of the haplotypes as weights to update the regression coefficients in an iterative manner (14) .
Results
Blood samples were available for 1,176 of the 1,581 participants in the brain case-control study. The genotyping success rate for the 12 SNPs ranged from 93.9% to 99.1%. Analysis of all SNPs in the control population did not detect deviation from HardyWeinberg equilibrium. Individuals with less education, and those in the oldest age group (70-90 years), were less likely to have samples sent for genotyping (Table 2) . Otherwise, the distribution of demographic characteristics for genotyped subjects was similar to the distribution for all study subjects. Relative to controls, subjects with glioma were proportionately more often male, whereas subjects with meningioma and acoustic neuroma were more often female. A lower proportion of subjects with meningioma and acoustic neuroma were in the youngest age bracket (<18 years) compared with controls. Table 3 summarizes the main effects of the 12 candidate SNPs involved in cell cycle control and apoptosis, for each brain tumor type. We observed no significant association between genotype and risk of any brain tumor (glioma, meningioma, or acoustic neuroma) for the following SNPs:
The Ex14-271A>T (rs13113) and Ex13+51G>C (D285H; rs1045485) polymorphisms in CASP8 were both associated with risk of meningioma: the AT and AA variants of CASP8 Ex14-271A>T were associated with significantly decreased risk of meningioma (OR AT , 0.8; 95% CI, 0.5, 1.2 and OR AA , 0.5; 95% CI, 0.3-0.9; P trend = 0.03), whereas the GC and CC variants of CASP8 Ex13+51G>C were associated with increased risk of meningioma (OR GC , 1.4; 95% CI, 0.9, 2.1 and OR CC , 3.6; 95% CI, 1.0, 13.1; P trend = 0.04) as well as acoustic neuroma (OR GC , 1.5; 95% CI, 0.8, 2.6 and OR CC , 5.6; 95% CI, 1.2, 26.6; P trend = 0.04). No association was observed between either of the CASP8 polymorphisms and glioma. The Ex14-271A>T (rs13113) and Ex13+51G>C (rs1045485) polymorphisms of CASP8 were found to be in linkage disequilibrium (D ¶ = 1.0, r 2 = 0.12). Haplotype analyses indicated that the CT haplotype of the two SNPs was associated with significantly increased risk of 
Gene polymorphism Chromosomal location
Genotype Controls (n = 553) Glioma (n = 388) Meningioma (n = 162) Acoustic neuroma (n = 73) meningioma (OR, 1.7; 95% CI, 1.1, 2.64), but not glioma or acoustic neuroma (Table 4) . The Ex8+49T>C variant of CCNH (rs2266690) was associated with increased risk of glioma (OR CT , 1.0; 95% CI, 0.7-1.3 and OR CC , 2.0; 95% CI, 1.0-3.9; P trend = 0.2) and acoustic neuroma (OR CT , 1.8; 95% CI, 1.0-3.1 and OR CC , 2.2; 95% CI, 0.6-7.8; P trend = 0.02), but was not associated with increased risk of meningioma. These trends were more strongly apparent in analyses restricted to non-Hispanic whites for both glioma (OR CT , 1.1; 95% CI, 0.8-1.5 and OR CC , 2.3; 95% CI, 1.1-4.7; P trend = 0.07) and acoustic neuroma (OR CT , 2.2; 95% CI, 1.2-3.9 and OR CC , 3.2; 95% CI, 0.9-11.9; P trend = 0.004).
Individuals with the variant allele of the CCND1 Ex4-1G>A polymorphism (rs603965) also showed some indication of increased risk for glioma (OR AG/GG , 1.3; 95% CI, 1.0-1.8).
Although the rare C-A haplotype (frequency = 0.01) was associated with decreased risk of glioma (OR, 0.5; 95% CI, 0.3-0.7), the global test was not statistically significant (P = 0.15). No CCND1 haplotype associations were observed for meningioma or acoustic neuroma. Significantly reduced risk of glioma was observed for individuals with the G variant of the MDM2 Ex12+162A>G (rs769412) polymorphism (OR AG/GG , 0.6; 95% CI, 0.4-0.9). We observed no significant gene-gene interaction between the TP53 Ex4+119C>G nonsynonymous SNP and the MDM2 Ex12+162A>G variant (results not shown). Risk estimates from unadjusted analyses were very similar to adjusted risk estimates. ORs for all statistically significant associations remained very similar when restricted to nonHispanic whites (Table 5) . Although gender-specific estimates were not as stable given smaller numbers, results were generally consistent in males and females ( Table 6 ). None of the observed associations passed the false discovery rate criterion of 15% chance of false-positive findings.
Discussion
Although the etiology of brain and central nervous system tumors is largely unknown, several lines of evidence indicate that events that alter cell cycle control and apoptosis pathways could be of importance. Among the few confirmed risk factors for brain tumors are certain rare predisposing genetic syndromes (15) (16) (17) . At least three of these syndromes, LiFraumeni syndrome, neurofibromatosis 1, and retinoblastoma, are characterized by germ line mutations in genes affecting progression through the cell cycle and apoptosis (TP53, NF1, and RB1, respectively). The importance of apoptosis and cell cycle control in brain tumor etiology is also suggested by mutations or loss of expression of cell cycle/apoptosis genes (PTEN, CDKN2A, MDM2, TP53, and RB) in brain tumors (3). More generally, these pathways are of importance in other cancers types, including breast, melanoma, and colon (1) .
Activation of the caspase (cysteine aspartyl-specific proteases) family of intracellular cysteine proteases is central to the initiation of apoptosis. CASP8 is the apical caspase in the tumor necrosis factor family death receptor pathway (extrinsic pathway) of apoptosis (18) . We observed novel associations between common genetic variants in CASP8 and brain tumors: Ex14-271A>T was associated with decreased risk of meningioma, whereas Ex13+51G>C (D285H) was associated with increased risk of meningioma and acoustic neuroma. Our haplotype analyses further implicates the chromosomal region indicated by the two CASP8 SNPs we evaluated; the significantly increased risk of meningioma observed with the CT haplotype suggests that this chromosomal region either harbors or is in linkage disequilibrium with a functional polymorphism that affects meningioma risk. Others have noted decreased risk of non -Hodgkin's lymphoma with the Ex14-271A>T variant (19) . Our finding of increased risk for the D285H nonsynonymous SNP is surprising because of its association with decreased breast cancer risk in other studies, including a large international case-control consortium (20) (21) (22) . Given that the functionality of this particular SNP has not been well characterized, it is premature to speculate on a mechanistic reason for the inverse direction and the possible role of chance cannot be ruled out. Elevated risks of glioma and acoustic neuroma were observed for several cell cycle gene polymorphisms. Molecular complexes of the cyclin-dependent kinases and their associated cyclins are responsible for sending out signals from the cell cycle clock to responder molecules that effect the transition of the cell through its cycle of growth and division (23) . We found evidence of increased risk of glioma with the Ex4-1G>A (G870A) polymorphism of the CCND1 gene coding for the cyclin D1 protein. Although no prior study has examined brain tumor risk with respect to the CCND1 G870A variant, increased risk has been observed with the A allele for several cancer sites, including bladder cancer, colorectal cancer, head and neck cancer, lung cancer, leukemia, and non -Hodgkin's lymphoma (24, 25) . Laboratory studies indicate that the A870 allele hinders splicing of the CCND1 protein and may cause production of a variant splice product (''transcript b''; ref. 24) . However, it is still unclear as to whether transcript b production is directly associated with the G/A 870 polymorphism or cancer risk.
In our study, we examined common SNPs in TP53 and MDM2, two genes central to cell cycle progression, cell survival, and genomic stability, and found no association with the well-studied exon 4 nonsynonymous SNP in TP53. This finding is consistent with null findings for this polymorphism in a Swedish study of 202 glioma and 164 meningioma cases (5), and a multicenter study of brain tumors (7), as well as one smaller study of brain tumors (4) . Although a possible association with this polymorphism was reported in a previous study with adult and pediatric astrocytomas, DNA for that analysis was extracted from tumor samples, raising the possibility that the mutations occurred after tumor initiation (6) . The potential importance of the TP53 gene in brain tumor risk, however, has been shown by the fact that other polymorphisms have been associated with differences in risk: an intron 6 variant (rs1625895) in TP53 has been associated with decreased risk of glioma and glioblastoma, as has the 1-2-2 haplotype of TP53 (promoter-codon72-intron; ref. 7) , whereas the CC-CG-CC haplotype (promoter-exon4-intron6) of TP53 has been associated with increased risk of glioma and meningioma (5) .
We observed decreased risk of glioma in individuals with the Ex12+162A>G polymorphism of the MDM2 gene. The relationship between this MDM2 polymorphism and brain tumor has not been previously reported in the literature. However, another common polymorphism in MDM2 (IVS+309T>G, rs2279744) has been associated with increased risk of gastric cancer (26) , esophageal cancer (27) , lung cancer (28, 29) , and bladder cancer (30) and may accelerate the risk of tumor formation in patients with familial breast cancer (31), LiFraumeni syndrome (32, 33) , colorectal cancer (34) , and gastric cancer (34) . Given that MDM2 is a strong negative regulator of the p-53 cascade, one might expect a gene-gene interaction between polymorphisms in these two genes. Although previous studies have reported gene-gene interactions between TP53 and the MDM2 309T>G polymorphism (34, 35), we did not detect any gene-gene interactions between the MDM2 Ex12+162A>G and the TP53 P72R polymorphisms. 
